Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency.

Front Immunol · 2022 · PMC9515892 · PMID 36189225

Europe PMC DOI

hedged sentences

0.6198

closest p · 12.4× alpha

0.6198

boldest claim

The sentences

did not reach statistical significancep-value = 0.6198not close (p > 0.1)

However, this finding did not reach statistical significance (Spearman, r=-0.1021, p-value = 0.6198, Figure 1C ).

also in 111,027 other papers

showed a trendno p-value reported

A multivariable logistic regression analysis demonstrated that the ChAdOx1 vaccine showed a trend in favor of non-neutralizing capability (OR 0.26, 95% CI 0.0055 - 6.4343), whereas the mRNA-1273 (OR 3.39, 95% CI 0.2421-73.6718) vaccine showed a trend towards higher likelihood of mounting neutralizing activity, with the BNT162b2 vaccine as reference ( Figure 2C ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.